Sagimet Biosciences
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 10
- Market Cap
- $97.8M
- Introduction
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). ...
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
FDA grants Breakthrough Therapy designation to Sagimet Biosciences' denifanstat for MASH treatment, supported by positive Phase 2b FASCINATE-2 trial data. Phase 3 program planned by end of 2024.
© Copyright 2024. All Rights Reserved by MedPath